Precision BioSciences, a gene editing company, has appointed Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific Advisory Board (SAB).

Drs. Sulkowski and Feld bring extensive experience in hepatitis clinical trials. Dr. Sulkowski is a renowned expert at Johns Hopkins University School of Medicine, while Dr. Feld holds leadership roles at Toronto General Hospital and the University of Toronto.

The SAB will guide the development of PBGENE-HBV, Precision’s potential treatment for chronic hepatitis B. The company anticipates submitting an Investigational New Drug (IND) or Clinical Trial Application (CTA) for PBGENE-HBV in late 2024.

Dr. Raymond Schinazi, an inaugural member of the SAB, praised Drs. Sulkowski and Feld’s expertise and leadership in the hepatitis field. Precision’s President and CEO, Michael Amoroso, emphasized the value of their insights as they prepare to advance PBGENE-HBV into clinical trials.

The appointments strengthen the SAB’s expertise in hepatitis and support Precision BioSciences’ commitment to developing innovative gene-editing therapies for chronic hepatitis B.

Source link: http://www.businesswire.com/news/home/20240620793683/en/Precision-BioSciences-Expands-Hepatitis-Scientific-Advisory-Board-with-Addition-of-World-Class-Clinical-Investigators-Mark-Sulkowski-M.D.-and-Jordan-Feld-M.D.-MPH-as-PBGENE-HBV-Program-Nears-Clinical-Readiness

Jon Napitupulu
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.